Overview of The Vape Cloud Hanging Over the FDA
This Wall Street Journal / Spotify Studios episode examines how vaping became a major political flashpoint inside the FDA, contributing to the resignation of Commissioner Dr. Marty Makary. The story connects public health concerns, industry lobbying, Trump-era politics, and a new FDA policy that could flood the market with more nicotine products.
Key Developments
- FDA Commissioner Marty Makary resigned after a turbulent tenure marked by internal conflict, criticism from the pharmaceutical industry, and pressure from both the White House and public health advocates.
- The vaping issue became the accelerant that helped push the administration toward ousting him.
- President Trump, who once opposed flavored vapes, reversed course in his 2024 campaign and promised to “save vaping” again.
- The FDA also announced a major policy shift: certain vaping and nicotine pouch products with pending applications may now be marketed while awaiting formal FDA action.
Why Vaping Became So Politically Important
From Public Health Panic to Political Identity
- In Trump’s first term, vaping was viewed as a youth-health crisis:
- flavored products were seen as highly appealing to teens
- schools and parents worried about widespread nicotine addiction
- a lung-injury outbreak intensified alarm
- In response, the Trump administration:
- raised the tobacco purchase age from 18 to 21
- backed an FDA ban on most flavored vape products
- allowed only limited flavors like menthol and tobacco
The 2024 Campaign Shift
- By the 2024 campaign, Trump saw vaping differently:
- as a way to appeal to young MAGA voters
- as a symbol of resisting the “public health establishment”
- as a market where he could promise to protect adult choice and business
- Vaping companies and nicotine-product advocates interpreted this as a signal that the FDA would become more permissive.
The Glass Case: The Flashpoint That Spurred Action
- A vaping company called Glass submitted an application for approval of a new age-gated vape device.
- The company argued the device was difficult for minors to use:
- required a phone app
- required age verification
- periodically forced re-verification
- Glass sought approval for flavors including:
- tobacco
- menthol
- mango
- blueberry
- FDA staff initially seemed receptive, but Makary’s office stalled the application, signaling concern that the technology was not enough to prevent youth access.
- That slowdown reportedly upset Trump, who then pressed advisers about why the FDA was moving so slowly.
- Shortly after, the flavored Glass products were approved, highlighting how quickly policy was shifting under political pressure.
Internal FDA and White House Tensions
Makary faced criticism from multiple sides:
- Pharmaceutical and biotech critics said he was too harsh on drug approvals and rare-disease treatments.
- White House insiders reportedly blamed him for disruptive personnel moves, including the controversial hiring/firing/rehiring cycle involving Dr. Vinay Prasad, who later stepped down.
- Anti-abortion activists were frustrated that he had not delivered a promised review of the abortion pill’s safety.
- Meanwhile, public health advocates feared he was being too lenient on vaping, while the industry saw him as blocking access to flavored products.
The Bigger FDA Policy Shift
- The FDA announced that companies with pending applications for electronic nicotine products and pouches could keep selling them without enforcement action.
- Supporters say this could:
- move the market away from illegal Chinese vapes
- create a more regulated supply chain
- help adult smokers access alternatives
- Critics warn it could:
- introduce hundreds or thousands of unapproved products
- weaken the legal standard for market authorization
- expose more young people to nicotine addiction
Public Health Concerns vs. Industry Goals
Public Health View
- Former FDA tobacco regulator Mitch Zeller warned the policy could let unreviewed products onto the market in a way that undermines the law’s intent.
- Makary, as a physician, reportedly believed:
- fruit-flavored vapes pose serious youth-risk
- teen vaping may still be undercounted
- approving those products would be irresponsible
Industry View
- Vaping companies argue that strict FDA delay has unintentionally encouraged:
- black-market products
- unregulated imports
- consumer demand for illicit flavored vapes
- They see the Trump administration’s new posture as a chance for long-awaited approvals and growth.
Leadership After Makary
- The White House named Kyle Diamantis as acting FDA commissioner.
- He is described as:
- an attorney
- a level-headed operator
- popular with FDA staff
- The episode suggests the next permanent commissioner will need to support Trump’s vaping agenda.
Main Takeaways
- Vaping is no longer just a health issue; it has become a political loyalty test inside the FDA.
- Trump’s pro-vaping turn helped reshape the agency’s direction.
- Makary’s resistance to flavored vape approvals appears to have been a key factor in his downfall.
- The FDA is now moving toward a more permissive nicotine market, which could dramatically expand the number of products available.
Notable Theme
The episode shows how an agency meant to regulate public health can become the center of a broader fight over:
- science vs. politics
- youth protection vs. consumer freedom
- legal regulation vs. black-market realities
- public health caution vs. industry expansion